Yana O. Sadovskaya

Yana O. Sadovskaya

Auto-generated profile, based on publicly available information

Yana O. Sadovskaya

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in Russian Journal of Oncology
Verified
Journal Article
Open access
PDF file
AKAnastasia O. Karimova
Anastasia O. Karimova
YSYana O. Sadovskaya
Yana O. Sadovskaya
OSOlga N. Solopova
Olga N. Solopova
Modern oncology needs to develop and implement antineoplastic agents that provide sustained remission without serious side effects. Immunotherapy and targeted therapy agents that activate innate immunity may address this issue. The stimulator of interferon genes (STING), an intracellular protein, mediates the synthesis of type I interferons, which have antiviral, antitumor, and antiproliferative properties. The multifaceted effects of interferons may be beneficial in cancer therapy. However, potential side effects of systemic interferon therapy underlie the need for the methods of stimulating them locally in the tumor nodule by targeting the STING pathway. STING is directly activated by the cyclic dinucleotide cGAMP. It is synthesized by the cyclic GMP-AMP synthase (cGAS) from adenosine triphosphate and guanosine triphosphate. However, cGAMP cannot be used as a therapeutic agent because it is unstable and only persists in the cell for a short period of time before being hydrolyzed. Therefore, researchers all over the world are working to synthesize new activators of the STING pathway. In cancer therapy, using STING activators as part of an immunoconjugate for targeted delivery to the tumor nodule is considered more effective. A monoclonal antibody against a tumor-specific antigen is the second component of the immunoconjugate. Given the high risk of tumor cell resistance to cytostatic drugs commonly used in current clinical practice, an immunoconjugate with a STING activator may provide advantages over existing therapies. Several immunoconjugates have already been tested in preclinical studies and are considered promising for drug development. However, further research is needed to study the properties of new compounds and improve their efficacy and tolerability. The search was performed in PubMed, eLIBRARY.RU, Google Scholar, NCBI ClinicalTrials, and PubChem and included publications from June to August 2025. The following search terms were used: STING protein, cGAS protein, cGAS-STING pathway, IFN-β, interferon-based treatment, type I IFN induction, antibody-drug conjugate, STING activation, STING agonist, and HER2-targeted therapies.

27 November 2025 in Russian Journal of Oncology
Verified
Journal Article
Closed access
YSYana O. Sadovskaya
Yana O. Sadovskaya
DGDmitriy V. Gusev
Dmitriy V. Gusev
AKAnastasia O. Karimova
Anastasia O. Karimova
MRMikhail A. Ryzhikov
Mikhail A. Ryzhikov
MKMargarita G. Khotuleva
Margarita G. Khotuleva
OSOlga N. Solopova
Olga N. Solopova
BACKGROUND: STING pathway activators with targeted delivery to tumor nodules are a promising option in cancer immunotherapy, especially as immunoconjugates. Existing compounds, such as MSA-2, are insufficiently effective as active immunoconjugate components, necessitating the development of new, more active compounds. AIM: The work aimed to examine the biological activity of the new compound SAD-2 and assess its potential as a new immunobiological drug for cancer therapy. METHODS: The work used contemporary methods of fine organic synthesis and analysis of the resulting compounds. MSA-2 was obtained from veratrole by multistage synthesis. SAD-2 was synthesized from MSA-2 by esterification with isopropyl alcohol in the presence of thionyl chloride. The antiproliferative activity of the compounds was assessed by the MTT method using colorectal cancer cell lines and human peripheral blood mononuclear cells. The induction of the interferon beta gene was assessed by real-time polymerase chain reaction using the human monocytic cell line THP-1. RESULTS: The new compound SAD-2 had 200–500 times higher antiproliferative activity according to IC50 than the existing compound MSA-2. Both MSA-2 and SAD-2 are active only in the presence of immune cells. SAD-2 showed 5–60 times higher relative induction of the IFNB1 gene than MSA-2, depending on the incubation time. CONCLUSION: SAD-2 is a promising new compound for developing immunoconjugates for targeted STING pathway activation in tumor nodules.

30 September 2025 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
MKMargarita G. Khotuleva
Margarita G. Khotuleva
YSYana O. Sadovskaya
Yana O. Sadovskaya
AKAnastasia O. Karimova
Anastasia O. Karimova
NVNikolay E. Varlamov
Nikolay E. Varlamov
DKDmitry Khochenkov
Dmitry Khochenkov
ДХД. А. Хоченков
Д. А. Хоченков
Background. Ferroptosis is a type of non-apoptotic iron-dependent form of regulated cell death. Ferroportin is the only exporter of iron from cells, however, the involvement of ferroportin in cell ferroptosisis poorly understood. Activation or blocking of ferroptosis pathways may provide a therapeutic strategy for the treatment of a number of diseases. Control of ferroportin expression will make it possible to select a more effective tumor therapy. Obtaining monoclonal antibodies to human ferroportin will help to further study its role in ferroptosis of tumor cells.Aim. Obtaining and characterization of monoclonal antibodies to human ferroportin.Materials and methods. Mouse monoclonal antibodies against a synthetic peptide corresponding to the ferroportin protein region were obtained using hybridomic technology. The peptide was synthesized by the method of solid-phase automatic synthesis.Results. A 15-membered peptide with the sequence ELKQLNLHKDTEPKP (ELK) was selected and synthesized. Conjugates of the synthetic peptide with carrier proteins were obtained. 4 stable hybridomic clones were obtained, and samples of monoclonal antibodies were obtained. The samples were successfully tested using methods of flow cytometry, enzyme immunoassay, and polyacrylamide gel electrophoresis.Conclusion. Four antibodies against ferroportin binding the ELK peptide were obtained and characterized. The antibodies can be used in further studies of iron transport in tumor cells.

20 November 2025 in Russian Journal of Oncology
Verified
Journal Article
Open access
AGAnatoliy S. Grinevich
Anatoliy S. Grinevich
YSYana O. Sadovskaya
Yana O. Sadovskaya
AKAnastasia O. Karimova
Anastasia O. Karimova
MRMikhail A. Ryzhikov
Mikhail A. Ryzhikov
MKMargarita G. Khotuleva
Margarita G. Khotuleva
DGDmitriy V. Gusev
Dmitriy V. Gusev
BACKGROUND: Monoclonal antibody (mAb)–drug immunoconjugates are a promising option in cancer immunotherapy. However, developing effective techniques of their synthesis remains relevant, especially when a small molecule has no mAb binding sites. AIM: The work aimed to synthesize immunoconjugates based on two modified rhodamine B molecules and four mAbs, and to examine their molecular and functional properties. METHODS: mAbs were conjugated to Rod-SMCC via reduced disulfide groups of immunoglobulin G (IgG). Rod-piperazine was added to oxidized IgG oligosaccharides. The synthesis was assessed using spectrophotometry. The activity of the resulting conjugates was assessed using enzyme-linked immunosorbent assay. The molecular heterogeneity of the resulting conjugates was assessed using high-performance chromatography. RESULTS: Rod-SMCC produced conjugates with all examined antibodies via thiol groups, with maximum saturation for each antibody. The maximum incorporation rate of approximately 10.96 ± 1.3 mol Rod per 1 mol IgG was observed for ICO 204, with approximately 5.19 ± 1.75 for trastuzumab. These Rod incorporation rates decreased after additional fractionation of the resulting immunoconjugates on a separating gel, amounting to 7.94 ± 1.8 for ICO 204 and 3.32 ± 1.2 for trastuzumab. The antigen-binding activity of ICO 204 immunoconjugates was comparable to that of native antibodies. The incorporation of Rod in immunoconjugates depended on the mAb fractionation technique. Acid elution during mAb fractionation on protein G decreased the incorporation of Rod in immunoconjugates. Rod-piperazine produced immunoconjugates with ICO 204 and trastuzumab via oxidized carbohydrate residues of antibodies. The maximum incorporation rate of rhodamine B in ICO 204 was 2.3 ± 0.3 mol per 1 mol IgG, with 0.2 ± 0.12 for trastuzumab. CONCLUSION: Chemical synthesis was used to produce two derivatives of Rod, which initially had no IgG binding sites. These compounds were used to synthesize model immunoconjugates with high Rod incorporation rates while maintaining antigen-binding activity. This work demonstrated that immunoconjugates can be produced using pharmaceutical substances with carboxyl groups that are unsuitable for such synthesis. Furthermore, it was shown that immunoconjugates can be synthesized through carboxyl group modification of pharmaceutical substances using piperazine and SMCC.

30 June 2026 in Problems of Virology
Verified
Journal Article
Open access
PDF file
NVNikolay E. Varlamov
Nikolay E. Varlamov
MRMikhail A. Ryzhikov
Mikhail A. Ryzhikov
NSNatalya Y. Serebryakova
Natalya Y. Serebryakova
DGDmitriy V. Gusev
Dmitriy V. Gusev
YSYana O. Sadovskaya
Yana O. Sadovskaya
СЮСеребрякова Наталья Юрьевна
Серебрякова Наталья Юрьевна
Introduction. Infection of canids with canine parvovirus (CPV), especially in puppies, leads to serious damage to the gastrointestinal tract in a short period of time, up to a fatal outcome. In this regard, early and rapid diagnosis is crucial for initiating therapy and preventing the spread of infection. In this connection, immunochromatographic analysis (ICA) is the preferred method because it allows rapid detection of virus infection. In addition, this method is highly specific and does not require complex laboratory equipment, which greatly simplifies its use in comparison with other common methods for detecting canine parvovirus. The aim of this study is the development of an ICA test system for the detection of the VP2 protein of canine parvovirus. Materials and methods. Monoclonal antibodies to the recombinant VP2 protein of canine parvovirus were obtained using hybridomic technology. Colloidal gold is synthesized by the citrate method. Results. Monoclonal antibodies (MABs) against the VP2 protein of canine parvovirus were obtained and characterized, colloidal gold (AuNPs) was synthesized, the conditions for conjugation of MABs with AuNPs were selected, and the optimal ratios of the components of the test system were determined. The visual limit detection (vLOD) was 1.56 ng/mL. The developed ICA test system has shown high diagnostic efficiency in model experiments with a known concentration of VP2, as well as in sick animals with a confirmed diagnosis. Conclusion. An ICA test system has been developed to determine the VP2 protein of canine parvovirus. The resulting test system can be used as a fast and effective diagnostic tool for detecting CVP in the canine clinical specimens.

15 July 2026 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
SSStepan D. Shceglov
Stepan D. Shceglov
ЩДЩеглов Степан Дмитриевич
Щеглов Степан Дмитриевич
YSYana O. Sadovskaya
Yana O. Sadovskaya
СОСадовская Я. О.
Садовская Я. О.
AKAnastasia O. Karimova
Anastasia O. Karimova
КМКозлова Ж. М.
Козлова Ж. М.
Background. One of the key components of innate immune signaling pathways, the STING (STimulator of INterferon Genes) protein, is currently a promising target for cancer immunotherapy. Activation of STING leads to the production of inflammatory cytokines, in particular type 1 interferons, which provide an antitumor immune response. The clinical potential of STING agonists is limited by their systemic toxicity due to their relatively non-specific action. One of the approaches to expand the therapeutic index of drugs is to modify the native structure of STING agonists to make them more sensitive to physiologically relevant stimuli. Another approach is to develop efficient delivery system that reduce the impact of encapsulated STING agonists on healthy tissues. Aim. Systematization and generalization the literature data on the development of delivery systems of STING agonists based on immunoconjugates, liposomes, and polymer nanoparticles. Results. The delivery systems discussed show significant potential for enhancing the efficacy of STING agonist-based immunotherapy for malignant neoplasms. As substances exhibiting therapeutically relevant activity in the nanomolar concentration range, STING agonists represent a suitable candidate as a payload of immunoconjugates. During the pharmaceutical development of such a delivery system, it is necessary to take into account the properties of its structural components, primarily the STING agonist itself. The result is almost always a unique product: a molecular construct capable of selectively delivering the STING activator to the tumor microenvironment while minimizing systemic side effects. Encapsulation of STING agonists, particularly cyclic dinucleotides, within nanoparticles serves as an effective tool for increasing their in vivo stability, improving cellular uptake, and reducing systemic toxicity. Conclusion. The development of innovative delivery systems is a critical factor for the successful clinical implementation of STING agonist-based biotherapy for malignant neoplasms. The flexibility of the structure of nanoplatforms allows for their further modification and optimization, including the improvements in manufacturing technology to obtain a stable product with specified characteristics.